Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. ElzEar Boulevard West, Laval, Canada

algomezus Feb. 3 at 3:18 PM

$BHC wow. I had a clear choice at 8 Teva or bhc. What a bad choice I made

1 · Reply

MikeCaymanTrades Feb. 1 at 1:26 AM

https://x.com/MikeJTrades/status/2017768840495575395 $BHC

0 · Reply

Sciguy67 Jan. 31 at 8:00 PM

$BHC earnings will be reported after market close. Not a good sign

1 · Reply

gary918 Jan. 30 at 4:43 PM

$BHC Let's hope these guys can start leaking some positive secondary endpoint data like they did the primary.

0 · Reply

JasDehradun Jan. 30 at 4:30 PM

$BHC RBC set a 12 months target price $US.X 10.00 on 27th Jan. Lets hope for the best. I am thinking of adding another 1K shares if prices hold today.

0 · Reply

kbingo12 Jan. 29 at 8:10 PM

$BHC 11 consecutive down days! No executive or board member buys in years...Stock down ~80% since Tom made CEO..he is not good at this

1 · Reply

Rpate Jan. 29 at 4:21 PM

$BHC salix scholarship news come soon.

2 · Reply

FU2 Jan. 29 at 3:32 PM

$BHC so what are we thinking? $5.50 close Friday. In all my years here, never once has management try to support stock price on drops. This This went from $8 to $5.50 fast. The wording on the Red-c sounded bearish. Insiders moving price around as needed.

2 · Reply

ZacksResearch Jan. 27 at 8:29 PM

$BHC slides again — is the RED-C failure a turning point? 📉 Bausch Health's stock fell 10% after the RED-C clinical program didn’t meet its primary endpoint, despite rifaximin SSD being safe. This setback comes as Xifaxan, a key revenue driver, is set to lose exclusivity in 2028. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2823757/bhcs-late-stage-liver-cirrhosis-studies-fail-stock-down?cid=sm-stocktwits-2-2823757-body-30573&ADID=SYND_STOCKTWITS_TWEET_2_2823757_BODY_30573

0 · Reply

ZacksResearch Jan. 27 at 7:29 PM

$BHC hit hard — a major liver drug setback just changed the story. ⚠️ Bausch Health shares slid after late-stage RED-C trials for rifaximin SSD failed, derailing plans to expand Xifaxan’s use in cirrhosis-related treatment — a clear blow to the pipeline. Get the full details here 👉 https://www.zacks.com/stock/news/2823757/bhcs-late-stage-liver-cirrhosis-studies-fail-stock-down?cid=sm-stocktwits-2-2823757-teaser-30572&ADID=SYND_STOCKTWITS_TWEET_2_2823757_TEASER_30572

0 · Reply

Bausch Health's brain dysfunction treatment fails late-stage trial

Jan 23, 2026, 7:45 AM EST - 11 days ago

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

Jan 21, 2026, 7:00 AM EST - 13 days ago

Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026

Jan 15, 2026, 3:15 AM EST - 20 days ago

Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 5, 2026, 7:00 AM EST - 4 weeks ago

Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 5:35 PM EST - 6 weeks ago

Bausch Health Announces Final Results and Expiration of Exchange Offers

Dec 8, 2025, 7:22 PM EST - 2 months ago

Bausch Health Announces Early Exchange Offer Results for Exchange Offers

Dec 2, 2025, 12:43 PM EST - 2 months ago

Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:00 AM EST - 2 months ago

Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China

Nov 24, 2025, 7:05 AM EST - 2 months ago

Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

Nov 18, 2025, 7:00 AM EST - 2 months ago

Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 8:18 AM EST - 2 months ago

Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Nov 13, 2025, 7:00 AM EST - 2 months ago

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Nov 11, 2025, 7:07 AM EST - 3 months ago

Bausch Health: Solid Q3 Performance Reinforces Deleveraging Path

Nov 5, 2025, 8:00 AM EST - 3 months ago

Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease

Nov 3, 2025, 4:30 PM EST - 3 months ago

Bausch + Lomb to Hold Investor Day on Nov. 13

Oct 31, 2025, 7:45 AM EDT - 3 months ago

Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results

Oct 29, 2025, 8:26 PM EDT - 3 months ago

Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 3 months ago

Bausch Health Announces Third Quarter 2025 Results

Oct 20, 2025, 10:57 AM EDT - 3 months ago

Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb

Oct 9, 2025, 7:00 AM EDT - 4 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

Sep 30, 2025, 8:00 AM EDT - 4 months ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 7:00 AM EDT - 4 months ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 29, 2025, 8:00 AM EDT - 4 months ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 11, 2025, 12:04 PM EDT - 5 months ago

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Sep 11, 2025, 8:35 AM EDT - 5 months ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 5 months ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 5 months ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 5 months ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 26, 2025, 8:00 AM EDT - 5 months ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Aug 21, 2025, 8:02 AM EDT - 5 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 18, 2025, 5:48 PM EDT - 6 months ago

Bausch + Lomb board members resign after Icahn agreement ends

Aug 15, 2025, 2:30 PM EDT - 6 months ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 12, 2025, 1:02 PM EDT - 6 months ago

Why Bausch Health Stock Surged By Nearly 20%

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Jul 30, 2025, 11:30 PM EDT - 6 months ago

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 6 months ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 2:21 PM EDT - 6 months ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Jul 29, 2025, 7:00 AM EDT - 6 months ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 6 months ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 6 months ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 6 months ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 10, 2025, 5:00 PM EDT - 7 months ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 4:15 PM EDT - 7 months ago

Bausch Health Appoints New Chief Accounting Officer

Jul 9, 2025, 8:00 AM EDT - 7 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 7, 2025, 8:00 AM EDT - 7 months ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Jul 2, 2025, 7:00 AM EDT - 7 months ago

Bausch Health to Announce Second Quarter 2025 Results on July 30

Jun 26, 2025, 4:30 PM EDT - 7 months ago

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Jun 22, 2025, 5:00 AM EDT - 8 months ago

A Billionaire Trump Supporter Is Buying These Two Stocks

PPTA

Jun 18, 2025, 11:01 AM EDT - 8 months ago

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

algomezus Feb. 3 at 3:18 PM

$BHC wow. I had a clear choice at 8 Teva or bhc. What a bad choice I made

1 · Reply

MikeCaymanTrades Feb. 1 at 1:26 AM

https://x.com/MikeJTrades/status/2017768840495575395 $BHC

0 · Reply

Sciguy67 Jan. 31 at 8:00 PM

$BHC earnings will be reported after market close. Not a good sign

1 · Reply

gary918 Jan. 30 at 4:43 PM

$BHC Let's hope these guys can start leaking some positive secondary endpoint data like they did the primary.

0 · Reply

JasDehradun Jan. 30 at 4:30 PM

$BHC RBC set a 12 months target price $US.X 10.00 on 27th Jan. Lets hope for the best. I am thinking of adding another 1K shares if prices hold today.

0 · Reply

kbingo12 Jan. 29 at 8:10 PM

$BHC 11 consecutive down days! No executive or board member buys in years...Stock down ~80% since Tom made CEO..he is not good at this

1 · Reply

Rpate Jan. 29 at 4:21 PM

$BHC salix scholarship news come soon.

2 · Reply

FU2 Jan. 29 at 3:32 PM

2 · Reply

ZacksResearch Jan. 27 at 8:29 PM

0 · Reply

ZacksResearch Jan. 27 at 7:29 PM

0 · Reply

OX50 Jan. 27 at 6:41 PM

$BHC

0 · Reply

Sciguy67 Jan. 27 at 2:46 PM

$BHC This was the title of a Zacks article from yesterday “Down 17.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Bausch (BHC)“. Sorry I could not get the link. It was on the yahoo finance website

0 · Reply

cameron5 Jan. 26 at 7:23 PM

$BHC https://ca.finance.yahoo.com/news/down-17-9-4-weeks-143502594.html

0 · Reply

truckersam Jan. 26 at 7:23 PM

$BHC let's go 4.25 average in , continue the beating.

1 · Reply

BillionerOfKing Jan. 26 at 6:34 PM

$BHC Current Stock Price: $5.80 Contracts to trade: $5.5 BHC Jan 30 2026 Call Entry: $0.30 Exit: $0.55 ROI: 83% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AKTN Jan. 26 at 5:55 PM

$BHC the only way this is going up is canning the entire fkin' management team and put it back together with $BLCO and put Saunders in the captain's chair. What good is BAUSH Health companies without BAUSCH and Lomb?? Opportunity cost of a lifetime.

4 · Reply

Estimize Jan. 26 at 4:03 PM

Wall St is expecting 1.21 EPS for $BHC Q4 [Reporting 02/18 AMC] http://www.estimize.com/intro/bhc?chart=historical&metric_name=eps&utm_cont

0 · Reply

Rpate Jan. 26 at 2:52 PM

$BHC Now all negative news are gone.

0 · Reply

FU2 Jan. 26 at 2:28 PM

$BHC give me a drop and pop today please!!!

0 · Reply

Billionaire1999 Jan. 26 at 11:42 AM

$BHC when will be the next clinical trial?

0 · Reply

marti837 Jan. 26 at 5:15 AM

$BHC This might be a good entry point.

0 · Reply

RunnerSignals Jan. 25 at 9:48 PM

$BHC $ORI $SHOP $NTNX $WST screaming oversold fear or opportunity? see which ones might bounce first https://stocksrunner.com/news/2026-01-25-identify-oversold-stocks-and-potential-reversals

0 · Reply

Market Cap	2.13B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	1.47
Forward PE	1.37
Profit Margin	-0.48%
Debt to Equity Ratio	59.11

Volume	1,408,800
Avg Vol	2,488,442
Day's Range	N/A - N/A
Shares Out	370.87M
Stochastic %K	12%
Beta	0.37
Analysts	Hold
Price Target	$7.43